Q-omics provides the consensus-scored MTCO2P16 profile across patient tissues and cancer cell-line models. MTCO2P16 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MTCO2P16 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, MTCO2P16 RNA expression shows 14,294 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, LUAD, and THYM as cancer lineages where MTCO2P16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCO2P16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCO2P16 survival associations across molecular data types. MTCO2P16 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCO2P16 RNA expression–survival associations across cancer types. High MTCO2P16 expression shows unfavorable associations in UVM, UCEC, CHOL and READ, but favorable associations in HNSC and LUSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MTCO2P16 RNA expression.
This table summarizes MTCO2P16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for MTCO2P16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCO2P16 shows lower tumor expression in BRCA, UCEC and PRAD and higher tumor expression in LUAD, CHOL and LUSC. The LUAD box plot shows higher MTCO2P16 RNA expression in tumor versus normal tissue (log2 FC = +1.775, t-test p < 0.001).
This table shows molecular features associated with MTCO2P16 in patient tissues and cancer cell lines. In patient samples, MTCO2P16 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
